Day 2

ACCESS-EUROPE: 12 months results in percutaneous treatment of mitral insufficiency .

solaci
solaci
533
0

Presentation Summary: ACCESS-EUROPE multicenter registry included 567 patients with severe mitral regurgitation treated with Mitral Clip in 14 European centers. Procedural success was high, (99.6%), while the 30-day mortality rate, (3.4%) and the one year rate, (18.2%) was acceptable. Annual mortality was more pronounced in those patients with a EuroSCORE greater than 20%, (76.3% vs. 86.4%, P <0.05).

ACCESS-EUROPE-slides

W. Schillinger
2012-08-26

Original title: ACCESS-EUROPE: An Observational Study of the MitraClip® System in Europe

Previous article
GRACE: Use of insulin glargine and fatty acids to reduce atherosclerosis progression.
Next article
FAME II: Ischemia guided (IG) percutaneous coronary intervention (PCI) is superior to medical treatment.
solaci
solaci

More articles by this author

GRACE: Use of insulin glargine and fatty acids to reduce atherosclerosis progression.

solaci - 0
Presentation Summary: There is a clear association between hyperglycemia and the development of atherosclerosis. The GRACE sub trial, (from ORIGIN study), evaluated the administration...

GARY: German Aortic Valve Registry.

solaci - 0
Presentation Summary: The German Aortic Stenosis Registry collected data from German centers. 13,860 patients who were undergoing valve replacement surgery or percutaneous valve implant...

FAST MI: AMI improved the survival associated with the clinical characteristics changes of patients in the French National Registry.

solaci - 0
Presentation Summary: The French National Registry included patients admitted with acute myocardial infarction between 1995 and 2010 (n = 6707). Over time, authors noted...

IABP-SHOCK II: Intra-aortic balloon use impact on 30-day mortality in patients with cardiogenic shock.

solaci - 0
 IABP-SHOCK II: Intra-aortic balloon use impact on 30-day mortality in patients with cardiogenic shock. Holger Thiele2012-08-26Original title: IABP-SHOCK II: Randomized comparison of intraaortic balloon counterpulsation versus...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Day 2

GRACE: Use of insulin glargine and fatty acids to reduce atherosclerosis progression.

Presentation Summary: There is a clear association between hyperglycemia and the development of atherosclerosis. The GRACE sub trial, (from ORIGIN...
solaci -
SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

Dr. Andrés Rodríguez - 0
According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

Dr. Andrés Rodríguez - 0
The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...

DAPT ≤30 Days After Drug-Coated Balloon Coronary Angioplasty

Dr. Juan Manuel Pérez - 0
Drug-coated balloon (DCB) coronary angioplasty without stent implantation has become a well-established alternative in several clinical scenarios, particularly in patients at high bleeding risk...